JTV-519 hemifumarate K201 hemifumarate,98.69%

产品编号:Bellancom-15293B| CAS NO:1435938-25-2| 分子式:C25H32N2O2S.1/2C4H4O4| 分子量:482.64

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用,

货号 包装 价格 库存与货期 购买量 操作
Bellancom-15293B
3000.00 杭州 北京(现货)
Bellancom-15293B
9000.00 杭州 北京(现货)
Bellancom-15293B
14400.00 杭州 北京(现货)

增值税发票√顺丰快递√订货电话:18601927057

JTV-519 hemifumarate K201 hemifumarate

产品介绍 JTV-519 hemifumarate (K201 hemifumarate) 是 Ca2+ 依赖性的肌质网 Ca2+ 刺激的 ATP 酶 (SERCA) 阻断剂。JTV-519 hemifumarate (K201 hemifumarate) 也是横纹肌中兰尼碱受体 (ryanodine receptors) 的部分激动剂。JTV-519 hemifumarate (K201 hemifumarate) 是一种心脏保护剂,具有抗心律失常作用。
生物活性

JTV-519 hemifumarate (K201 hemifumarate) is a Ca2+-dependent blocker of sarcoplasmic reticulum Ca2+-stimulated ATPase (SERCA) and a partial agonist of ryanodine receptors in striated muscle. Antiarrhythmic and cardioprotective properties.

体外研究

JTV-519 (K201) inhibits inward Ca2+ movement into large unilamellar vesicles (LUV) caused by annexin V in a dose-dependent manner. In the presence of 50 nM annexin V and 400 μM Ca2+, 3 μM JTV-519 shows significant inhibition of Ca2+ movement due to annexin V, and 50% inhibition is achieved at 25 μM K201.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

JTV-519 (0.5mg/kg/h, i.v., 2 h before the surgery) improves cardiac function in CLP mice, where the fractional shortening (FS) and ejection fraction (EF) are significantly increased as compared with CLP mice without JTV-519 treatment.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Wild type male C57BL/6 mice weighing 18-22g with polymicrobial sepsis produced by cecal ligation and puncture (CLP)
Dosage: 0.5 mg/kg/h
Administration: Applied intraperitoneally 2 h before the surgery
Result: Improved cardiac function, where the EF and FS were significantly increased.
体内研究

JTV-519 (0.5mg/kg/h, i.v., 2 h before the surgery) improves cardiac function in CLP mice, where the fractional shortening (FS) and ejection fraction (EF) are significantly increased as compared with CLP mice without JTV-519 treatment.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Wild type male C57BL/6 mice weighing 18-22g with polymicrobial sepsis produced by cecal ligation and puncture (CLP)
Dosage: 0.5 mg/kg/h
Administration: Applied intraperitoneally 2 h before the surgery
Result: Improved cardiac function, where the EF and FS were significantly increased.
性状Solid
溶解性数据
运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
参考文献

相关文档

化学品安全说明书(MSDS)

下载MSDS

质检证书(COA)

相关产品


服务热线

13911702513
18601927057

微信客服